Alfuzosin Hydrochloride Tablet, Film Coated, Extended Release
Product Images NDC 65862-249

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Alfuzosin Hydrochloride (NDC 65862-249). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aurobindo Pharma Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Figure-1 (Alfuzosin Fig1)

Figure-1 (Alfuzosin Fig1)
A line graph comparing Alfuzosin plasma concentration (ng/mL) over 24 hours under fed and fasted conditions. The x-axis shows time in hours, and the y-axis shows plasma concentration. Two lines illustrate higher concentrations with food intake and lower with fasting, both with error bars representing variability.*
FDA Label Image

Figure 2 — Mean Change From Baseline In Ipss Total Symptom Score: Trial 1 (Alfuzosin Fig2)

Figure 2 — Mean Change From Baseline In Ipss Total Symptom Score: Trial 1 (Alfuzosin Fig2)
Line graph depicting mean change from baseline over 84 days of treatment for Alfuzosin Hydrochloride versus placebo groups. The graph shows two lines: one for placebo with minimal decrease and one for Alfuzosin Hydrochloride with a larger decrease in mean change. The x-axis represents days of treatment and the y-axis represents mean change.*
FDA Label Image

Figure 3 — Mean Change From Baseline In Ipss Total Symptom Score: Trial 2 (Alfuzosin Fig3)

Figure 3 — Mean Change From Baseline In Ipss Total Symptom Score: Trial 2 (Alfuzosin Fig3)
A line graph depicting the mean change from baseline in IPSS Total Symptom Score over days of treatment for placebo and Alfuzosin Hydrochloride groups. Two lines show a greater decrease in symptom score for the Alfuzosin Hydrochloride group compared to placebo across treatment days 0, 28, 90, and 84.*
FDA Label Image

Figure 4 — Mean Change From Baseline In Ipss Total Symptom Score: Trial 3 (Alfuzosin Fig4)

Figure 4 — Mean Change From Baseline In Ipss Total Symptom Score: Trial 3 (Alfuzosin Fig4)
A line graph depicting mean change from baseline in IPSS Total Symptom Score over days of treatment for Alfuzosin Hydrochloride versus placebo. The x-axis represents days of treatment (0, 28, 56, 84), and the y-axis shows the change from baseline score, with Alfuzosin Hydrochloride showing a greater decrease compared to placebo.*
FDA Label Image

Figure 5 — Mean Change From Baseline In Peak Urine Flow Rate (ml/s): Trial 1 (Alfuzosin Fig5)

Figure 5 — Mean Change From Baseline In Peak Urine Flow Rate (ml/s): Trial 1 (Alfuzosin Fig5)
A line graph showing mean change from baseline in peak urine flow rate (mL/s) over days of treatment for two groups: placebo (N=167) and Alfuzosin Hydrochloride (N=170). The Alfuzosin group shows a higher increase, approximately 1.7 mL/s, maintained from day 28 to day 84, while the placebo group remains below 0.5 mL/s. Statistical significance is indicated at p < 0.001.*
FDA Label Image

Figure 6 — Mean Change From Baseline In Peak Urine Flow Rate (ml/s): Trial 2 (Alfuzosin Fig6)

Figure 6 — Mean Change From Baseline In Peak Urine Flow Rate (ml/s): Trial 2 (Alfuzosin Fig6)
A line graph depicting mean change from baseline in peak urine flow rate (mL/s) over days of treatment for Alfuzosin Hydrochloride compared to placebo. The x-axis shows days of treatment up to 84 days, and the y-axis measures mean change in mL/s. Alfuzosin Hydrochloride shows a greater increase in peak urine flow rate over time compared to placebo.*
FDA Label Image

Figure 7 — Mean Change From Baseline In Peak Urine Flow Rate (ml/s): Trial 3 (Alfuzosin Fig7)

Figure 7 — Mean Change From Baseline In Peak Urine Flow Rate (ml/s): Trial 3 (Alfuzosin Fig7)
A line chart depicting the mean change from baseline in peak urine flow rate (mL/s) over 84 days of treatment for two groups: placebo and Alfuzosin Hydrochloride. The x-axis represents days of treatment, while the y-axis shows mean change in mL/s. Data points show higher increases for the Alfuzosin Hydrochloride group compared to placebo.*
FDA Label Image

Package Label-principal Display Panel (10 mg (30 Tablet Bottle))

Package Label-principal Display Panel (10 mg (30 Tablet Bottle))
Label for Alfuzosin Hydrochloride Extended-Release Tablets USP 10 mg, film-coated tablets, extended-release. The label indicates a package size of 30 tablets. Distributed by Aurobindo Pharma USA, Inc., made in India. Includes dosage and storage instructions with a barcode on the right side.*
FDA Label Image

Structure (Alfuzosin Str)

Structure (Alfuzosin Str)
Chemical structure of Alfuzosin Hydrochloride, showing its molecular configuration with labeled functional groups, including methoxy groups, amine groups, and hydrochloride salt form.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.